Allstocks.com's Bulletin Board Post A Reply
my profile login | register | search | faq | forum home

» Allstocks.com's Bulletin Board » .11 and Up! » ProtoKinetix Announces the Resumption of Phase 1b Clinical Trials for the use of AAGP » Post A Reply

Post A Reply
Login Name:
Password:
Message Icon: Icon 1     Icon 2     Icon 3     Icon 4     Icon 5     Icon 6     Icon 7    
Icon 8     Icon 9     Icon 10     Icon 11     Icon 12     Icon 13     Icon 14    
Message:

HTML is enabled.
UBB Code™ is enabled.

 

Instant Graemlins Instant UBB Code™
Smile   Frown   Embarrassed   Big Grin   Wink   Razz  
Cool   Roll Eyes   Mad   Eek!   Confused   BadOne  
Good Luck   More Crap   Wall Bang   Were Up   Were Down    
Insert URL Hyperlink - UBB Code™   Insert Email Address - UBB Code™
Bold - UBB Code™   Italics - UBB Code™
Quote - UBB Code™   Code Tag - UBB Code™
List Start - UBB Code™   List Item - UBB Code™
List End - UBB Code™   Image - UBB Code™

What is UBB Code™?
Options


Disable Graemlins in this post.


 


T O P I C     R E V I E W
jackbequick  - posted
ProtoKinetix Announces the Resumption of Phase 1b
Clinical Trials for the use of AAGP® Treated Islet Cells in
the Treatment of Type 1 Diabetes

Marietta, Ohio, April 22, 2020

ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX), a clinical-stage biomedical company, today announced Phase I clinical trials of AAGP® (PKX-001) treated islet cells have resumed at the University of Alberta, Edmonton. All clinical trials were paused in 2020 due to COVID-19 restrictions in the province.

The Phase 1 trials, conducted by renowned surgeon Dr. James Shapiro, focus on the impact of PKX-001 treated islet cells transplanted into patients suffering from Type-1 diabetes. Data from the initial Phase 1a illustrated the safety of using the patented PKX-001 molecule as an enhancement to transplanted islet cells in six study patients. Study protocols have been modified for Phase 1b, focusing on the efficacy of the PKX-001 treated islet cells transplanted in a process known as the Edmonton Protocol. Under the new protocols, the first patient out of a total of 10 has entered into this Phase 1b trial Type-1 diabetes patients to be treated.

PKX-001 is the designation given to the lead drug product molecule of the AAGP® family. Islet cell transplants are well recognized as a viable and effective treatment for Type-1 diabetes. The study will treat islet cells with PKX-001 prior to transplantation into informed patient participants. The clinical trials primary objective is to establish patient safety. We are now looking at optimizing these trials for efficacy by dose escalation. The study will also be making observations related to indications of protection from tacrolimus toxicity and enhanced engraftment survival of the transplanted cells. The trial follows extensive preclinical evaluation in experimental models (to learn more, refer to this link: Diabetes).

The trial is being led by Dr. James Shapiro, MD, PhD, FRCSC, MSM FCAHS, AHS Director of Clinical Islet and Living Donor Liver Transplant Programs, Canada Research Chair in Transplant Surgery and Regenerative Medicine, Professor of Surgery, Medicine and Surgical Oncology, University of Alberta.

“We are delighted to have increased dose and reactivated this exciting AAGP® trial, andtransplanted our next patient on April 12, 2021. We eagerly await definitive results as we move forward.” – Dr. James Shapiro

Click here for Dr. James Shapiro Video

Dr. James Shapiro Bio

About the Edmonton Protocol
Diabetes Research Institute Foundation Canada Video

To obtain additional information and updates regarding this trial please use the following
link: Clinicaltrials.gov – Islet Transplantation Using PKX-001.

See the promising research of AAGP® and results to date. The Islet Cell Transplantation study is encouraging and additionally supports ProtoKinetix’s efforts to develop PKX-001 for other indications, including (but not limited to) stem cell transplantation in Wet and Dry Age-related Macular Degeneration and potential use in Dry Eye Disease. ProtoKinetix aims to investigate PKX-001 for these and other indications based on robust preclinical evidence.


Visit our new website at ProtoKinetix.com for more information and to join our email list.
 



Contact Us | Allstocks.com Message Board Home

© 1997 - 2021 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share